Abstract
In a simulation study of inference on population pharmacokinetic parameters, two methods of performing tests of hypotheses comparing two populations using NONMEM were evaluated. These two methods are the test based upon 95% confidence intervals and the likelihood ratio test. Data were simulated according to a monoexponential model and, in that context, power curves for each test were generated for (i)the ratio of mean clearance and (ii)the ratio of the population standard deviations of clearance. To generate the power curves, a range of these parameters was employed; other pharmacokinetic parameters were selected to reflect the variability typically present in a Phase II clinical trial. For tests comparing the means, the confidence interval tests had approximately the same power as the likelihood ratio tests and were consistently more faithful to the nominal level of significance. For comparison of the standard deviations, and when the volume of information available was relatively small, however, the likelihood ratio test was more able to detect differences between the two groups. These results were then compared to results on parameter estimation in order to gain insight into the question of power. As an example, the nonnormality of estimates of the ratio of standard deviations plays an important role in explaining the low power for the confidence interval tests. We conclude that, except for the situation of modeling standard deviations with only sparse information, NONMEM produces tests of significance that are effective at detecting clinically significant differences between two populations.
Similar content being viewed by others
References
L. B. Sheiner, B. Rosenberg, and V. V. Marathe. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.J. Pharmacokin. Biopharm. 5:445–479 (1977).
L. B. Sheiner, and S. L. Beal. A note on confidence intervals with extended least squares parameter estimates.J. Pharmacokin. Biopharm. 15:93–98 (1987).
D. B. White, C. A. Walawander, Y. Tung, and T. H. Grasela. An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.J. Pharmacokin. Biopharm. 19:87–112 (1991).
T. H. Grasela, E. J. Antal, L. Ereshefsky, B. G. Wells, R. L. Evans, and R. B. Smith. An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction.Clin. Pharmacol. Ther. 42:433–441 (1987).
N. M. Graves, T. M. Ludden, G. B. Holmes, R. H. Fuerst, and I. E. Leppik. Pharmacokinetics of felbamate, a novel antiepileptic drug: Application of mixed-effect modeling to clinical trials.Pharmacotherapy 9:372–376 (1989).
K. Fattinger, S. Vozeh, A. Olafsson, J. Vleck, M. Wenk, and F. Follath. Netilmicin in the neonate: Population pharmacokinetic analysis and dosing recommendations.Clin. Pharmacol. Ther. 50:55–65 (1991).
J. Grevel, P. Thomas, and B. Whiting. Population pharmacokinetic analysis of bisoprolol.Clin. Pharmacokin. 17:53–63 (1989).
M. S. Driscoll, T. M. Ludden, D. T. Casto, and L. C. Littlefield. Evaluation of theophylline pharmacokinetics in a pediatrie population using mixed effects models.J. Pharmacokin. Biopharm. 17:141–168 (1989).
M. A. Stephens. EDF statistics for goodness of fit and some comparisons.J. Am. Statist. Assoc. 69:730–737 (1974).
Author information
Authors and Affiliations
Additional information
Partial support from the Upjohn Company, NIH-BRSG SO RR 07066, and the Burroughs Wellcome Foundation.
Rights and permissions
About this article
Cite this article
White, D.B., Walawander, C.A., Liu, D.Y. et al. Evaluation of hypothesis testing for comparing two populations using NONMEM analysis. Journal of Pharmacokinetics and Biopharmaceutics 20, 295–313 (1992). https://doi.org/10.1007/BF01062529
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01062529